PURPOSE: Community oncology practices frequently manage chemotherapy-associated toxicities, which may disrupt treatment, impair quality of life, and induce unplanned service use. We sought to understand the patterns and correlates of unplanned health care service use among patients receiving first-cycle chemotherapy at five community-based ambulatory oncology practices. PATIENTS AND METHODS: A survey study examined the dichotomous outcome of unplanned service use, defined as oncologist visits, emergency department visits, and hospitalizations, resulting from toxicity-related factors. Newly diagnosed patients with breast, lung, head and neck, or colorectal cancer or non-Hodgkin lymphoma were recruited during the first chemotherapy cycle. Before beginning the second cycle of chemotherapy, patients completed a questionnaire that measured unplanned service use and overall distress, plus severity of nausea, vomiting, diarrhea, constipation, mouth sores, intravenous catheter problems, pain, fever and chills, extremity edema, and dyspnea on a 5-point scale (1, did not experience; 5, disabling). Medical record reviews captured chemotherapy doses, comorbid conditions, and supportive care interventions. Mixed-effects logistic regression was used to identify factors associated with unplanned service use, with random effects specified for each clinic. RESULTS: Among 106 patients (white, 98%; female, 74.5%; mean age ± standard deviation, 60 ± 11 years), frequently reported toxicities were pain, nausea, diarrhea, and constipation. Thirty-six patients (34%) reported unplanned service use: 29% reported oncologist visits, 14% reported emergency department visits, and 8% reported hospitalizations. Factors significantly associated with unplanned service use were high patient-reported distress and receipt of colony-stimulating factor. CONCLUSION: Service use resulting from toxicity-related factors occurs frequently in community oncology settings. Monitoring toxicity patterns and outcomes can inform proactive symptom management approaches to reduce toxicity burden between scheduled visits.
PURPOSE: Community oncology practices frequently manage chemotherapy-associated toxicities, which may disrupt treatment, impair quality of life, and induce unplanned service use. We sought to understand the patterns and correlates of unplanned health care service use among patients receiving first-cycle chemotherapy at five community-based ambulatory oncology practices. PATIENTS AND METHODS: A survey study examined the dichotomous outcome of unplanned service use, defined as oncologist visits, emergency department visits, and hospitalizations, resulting from toxicity-related factors. Newly diagnosed patients with breast, lung, head and neck, or colorectal cancer or non-Hodgkin lymphoma were recruited during the first chemotherapy cycle. Before beginning the second cycle of chemotherapy, patients completed a questionnaire that measured unplanned service use and overall distress, plus severity of nausea, vomiting, diarrhea, constipation, mouth sores, intravenous catheter problems, pain, fever and chills, extremity edema, and dyspnea on a 5-point scale (1, did not experience; 5, disabling). Medical record reviews captured chemotherapy doses, comorbid conditions, and supportive care interventions. Mixed-effects logistic regression was used to identify factors associated with unplanned service use, with random effects specified for each clinic. RESULTS: Among 106 patients (white, 98%; female, 74.5%; mean age ± standard deviation, 60 ± 11 years), frequently reported toxicities were pain, nausea, diarrhea, and constipation. Thirty-six patients (34%) reported unplanned service use: 29% reported oncologist visits, 14% reported emergency department visits, and 8% reported hospitalizations. Factors significantly associated with unplanned service use were high patient-reported distress and receipt of colony-stimulating factor. CONCLUSION: Service use resulting from toxicity-related factors occurs frequently in community oncology settings. Monitoring toxicity patterns and outcomes can inform proactive symptom management approaches to reduce toxicity burden between scheduled visits.
Authors: Eric C Schneider; Jennifer L Malin; Katherine L Kahn; Ezekiel J Emanuel; Arnold M Epstein Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Ethan Basch; David Artz; Alexia Iasonos; John Speakman; Kevin Shannon; Kai Lin; Charmaine Pun; Henry Yong; Paul Fearn; Allison Barz; Howard I Scher; Mary McCabe; Deborah Schrag Journal: J Am Med Inform Assoc Date: 2007-02-28 Impact factor: 4.497
Authors: Elizabeth A Chrischilles; Jane F Pendergast; Katherine L Kahn; Robert B Wallace; Daniela C Moga; David P Harrington; Catarina I Kiefe; Jane C Weeks; Dee W West; S Yousuf Zafar; Robert H Fletcher Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich Journal: Health Serv Res Date: 2020-10-30 Impact factor: 3.402
Authors: Arthur S Hong; Danh Q Nguyen; Simon Craddock Lee; D Mark Courtney; John W Sweetenham; Navid Sadeghi; John V Cox; Hannah Fullington; Ethan A Halm Journal: JCO Oncol Pract Date: 2021-05-26
Authors: Steven J Katz; Timothy P Hofer; Christopher R Friese; Jordan M Harrison; Nancy K Janz; Reshma Jagsi; Monica Morrow; Yun Li; Ann S Hamilton; Kevin C Ward; Allison W Kurian Journal: Cancer Date: 2017-01-24 Impact factor: 6.921
Authors: Melissa Adair; Barbara Murphy; Sujatha Yarlagadda; Jie Deng; Mary S Dietrich; Sheila H Ridner Journal: Integr Cancer Ther Date: 2018-01-22 Impact factor: 3.279
Authors: Ann Langius-Eklöf; Marie-Therése Crafoord; Mats Christiansen; Maria Fjell; Kay Sundberg Journal: BMC Cancer Date: 2017-07-04 Impact factor: 4.430